Celltrion, Inc. Starts Phase 1 of Clinical Trials For its New Influenza Vaccine According to BAC Report

03 May 2013 • by Natalie Aster

LONDON – On April 26th Celltrion received permission to start Phase 1 of clinical trials of its new vaccine CT-P27 for several flu strains including H7N9 virus that is regarded as lethal in China. The company acquired approval from England’s Medicines and Healthcare products Regulatory Agency (MHRA), and the trials are to start in May. In vitro and in vivo experiments on laboratory mice and ferrets showed this vaccine’s efficacy against various human influenza strains.

The new formulation is believed to be efficient even when such popular treatments as Relenza or Tamiflu are not helping. Currently over 50% of virus strains are resistant to those treatments, and CT-P27 is supposed to solve the problem.

Celltrion is a financially successful company. It ended 2012 with positive trends. Revenue rocketed up 25.5% to KRW 350.2 B, gross profit increased by 13% to KRW 256.3 B, operating and net income added 9.4% and 3.9%, and amounted KRW 195.4 B and KRW 174.4 B, respectively. The year was ended with strong quarter strengthening company’s position: revenue and gross profit comprised KRW 109.4 B and KRW 76.7 B, operating and net income ended up with KRW 62.6 B and KRW 54.2 B, respectively.

Founded in 2002 and headquartered in Incheon (South Korea), Celltrion engages in development of vaccines and biosimilars against viral diseases. In 2012 the company launched its first biosimilar drug, Remsima, that is aimed at treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Adult Crohn's Disease. Psoria.sis. Psoriatic Arthritis. Celltrion has several vaccines to be released soon: CT-P6 (against breast cancer) and CT-P10 (against Non-Hodgkin's Lymphoma and Rheumatoid Arthritis). The company also has several formulations still undergoing clinical studies: CT-P4 (against lung cancer), CT-P19 (against rabies), CT-P24 (against Hepatitis B Virus), CT-P25 (Pandemic /seasonal flu vaccine), CT-P26 (against breast cancer).

Get full details listing of the company’s products, competitors, news and experts’ forecasts can be found in the report “Celltrion, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis” developed by Business Analytic Center (BAC) and recently published by Market Publishers Ltd.

Report Details:

Celltrion, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Date: Apr, 2013
Pages: 64

More company reports featuring SWOT and financial information, industry and competitors analysis can be found in Company Reports Catalog.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970